A
Arturo Molina
Researcher at Janssen Pharmaceutica
Publications - 232
Citations - 21831
Arturo Molina is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Abiraterone acetate & Prostate cancer. The author has an hindex of 64, co-authored 232 publications receiving 20235 citations. Previous affiliations of Arturo Molina include Duke University & Harvard University.
Papers
More filters
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan,Matthew R. Smith,Johann S. de Bono,Arturo Molina,Christopher J. Logothetis,Paul de Souza,Karim Fizazi,Paul N. Mainwaring,Josep M. Piulats,Siobhan Ng,Joan Carles,Peter F.A. Mulders,Ethan Basch,Eric J. Small,Fred Saad,D. Schrijvers,Hendrik Van Poppel,Som D. Mukherjee,Henrik Suttmann,Winald R. Gerritsen,Thomas W. Flaig,Daniel J. George,Evan Y. Yu,Eleni Efstathiou,Allan J. Pantuck,Eric Winquist,Celestia S. Higano,Mary-Ellen Taplin,Youn C. Park,Thian Kheoh,Thomas W. Griffin,Howard I. Scher,Dana E. Rathkopf +32 more
TL;DR: Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi,Howard I. Scher,Arturo Molina,Christopher J. Logothetis,Kim N. Chi,Robert Jones,John Staffurth,Scott North,Nicholas J. Vogelzang,Fred Saad,Paul N. Mainwaring,S. J. Harland,Oscar B. Goodman,Cora N. Sternberg,Jinhui Li,Thian Kheoh,C. M. Haqq,Johann S. de Bono +17 more
TL;DR: It is confirmed that abiraterone acetate significantly prolongs overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel treatment.
Journal ArticleDOI
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan,Matthew R. Smith,Karim Fizazi,Fred Saad,Peter F.A. Mulders,Cora N. Sternberg,Kurt Miller,Christopher J. Logothetis,Neal D. Shore,Eric J. Small,Joan Carles,Thomas W. Flaig,Mary-Ellen Taplin,Celestia S. Higano,Paul de Souza,Johann S. de Bono,Thomas W. Griffin,Peter De Porre,Margaret K. Yu,Youn C. Park,Jinhui Li,Thian Kheoh,V. Naini,Arturo Molina,Dana E. Rathkopf +24 more
TL;DR: Treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant, and further support the favourable safety profile of abiraton acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard,Alison Reid,Roger A'Hern,Chris Parker,Nikhil Babu Oommen,Elizabeth Folkerd,Christina Messiou,L Rhoda Molife,G. Maier,Emilda Thompson,David Olmos,Rajesh Sinha,Gloria Lee,Mitch Dowsett,Stan B. Kaye,David P. Dearnaley,Thian Kheoh,Arturo Molina,Johann S. de Bono +18 more
TL;DR: YP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven.